The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    BlossomHill Therapeutics and Vogenx became the fifth and sixth drug startups to join the IPO queue in July alone. Meanwhile, a biotech that revealed its IPO plans in April hiked its coming offering. 

    Updated 6 hours ago
  • Pills lie on top of hundred dollar bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Jasper gets a lifeline in merger with immune drugmaker Kira

    The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.  

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

    The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.

  • A sign spelling Merck hangs on the side of an office building
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck ADC, in China study, shows potential to replace chemo in lung cancer

    The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer. 

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Celcuity gains FDA approval for closely watched breast cancer drug

    Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

    Updated July 15, 2026
  • An illustration of beta amyloid plaques and tau in the brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Brain drug revival

    Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs

    The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.

  • A clear drop with a dollar symbol is pipetted into a test tube.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Biotech startup funding gap widens despite rebound in VC investment

    Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.

  • A photo of the street sign for Wall Street, in front of a row of American flags.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Braveheart, Attovia join next wave of biotech IPOs

    The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs. 

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    With its purchase of AtaiBeckley, Eli Lilly has now acquired 11 drugmakers this year — by far the most among its pharmaceutical peers.

    Updated July 16, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals

    J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.

  • The exterior of the Law Courts Building in the Cayman Islands.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Judge orders Apple Tree partner to forfeit oversight of venture fund

    The ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing — and a bid by general partner Seth Harrison for the firm’s portfolio companies.

    Updated July 14, 2026
  • African American Woman With Itchy Skin. Allergy Or Psoriasis
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill

    Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde. 

  • A closeup of an entryway that reads the Federal Trade Commission.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    CVS Caremark reaches settlement with FTC over insulin suit

    Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, including requiring the PBM to stop preferring higher cost versions of drugs on standard formularies.

  • A colorful stock market ticker
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Q32 bounces back to claim study success for alopecia drug

    Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations. 

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    Including three deals announced Tuesday, Chinese drugmakers have formed more than 100 licensing pacts with their U.S. and European counterparts since the start of 2025, BioPharma Dive data show.

    Updated July 14, 2026
  • A candlestick stock chart is seen out of focus against a background of $100 dollar bills in this composite stock image.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Draig bags another $65M to speed testing of brain drugs

    The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder. 

  • An illustration of pain in the colon.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Freenome colorectal cancer test data improve on earlier results

    The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Agenus surges on study pivot; Apnimed lines up an IPO

    Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK, Hansoh ADC extends survival in lung cancer study

    GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers. 

  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    Roche scraps two Ionis-partnered Huntington’s drugs

    The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.

  • An anatomical model of the heart sits on a desk in a doctor's office
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca, Ionis drug fails big heart disease study in major setback

    Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

    The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.

  • paperwork art
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trump administration

    HHS plan to speed drug research won’t remove ‘self-inflicted’ delays

    U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

    FDA
  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    On back-to-back days, AI drug discovery specialist Chai Discovery and radiopharmaceuticals developer AdvanCell raised two of the year’s top venture rounds involving the investment firms BioPharma Dive tracks.

    Updated July 15, 2026
  • An AstraZeneca logo stands atop an office building in Shanghai, China.
    Image attribution tooltip
    Robert Way via Getty Images
    Image attribution tooltip
    China competition

    AstraZeneca, GSK intensify China ties with Sino Biopharm deals

    The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.